Composition for treating oral cancer as well as preparation method and application thereof
By using traditional Chinese medicine compositions of Huangcen, roasted licorice, peony, jujube, Chonglou and Sophora ginseng, drugs for the treatment of oral cancer were prepared, which solved the problem of oral squamous cell carcinoma cell migration and achieved inhibition of cancer cell proliferation and the effect of migration, assist in the treatment of oral cancer.
Patent Information
- Application Number
- CN202411067620.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-06
- Publication Date
- 2024-11-19
AI Technical Summary
Treatment of oral squamous cell carcinoma, cells are still prone to spread after surgical resection, resulting in high morbidity and mortality. It is difficult for existing treatments to effectively inhibit cancer cell migration.
A Chinese medicine composition including Huang Cen, roasted licorice, peony, jujube, Chonglou and Sophora ginseng is prepared by mixing and boiling methods in a specific proportion, and further prepared ointments, granules, tablets or capsules are further prepared. , used to assist in the treatment of oral cancer.
This composition has the effect of clearing heat, anti-inflammatory and analgesic effects, effectively inhibits the migration ability of oral cancer cells, induces apoptosis, assists in the treatment of oral squamous cell carcinoma, significantly reduces cell survival and mobility, and improves the cytotoxicity of CD8+ T cells.
Smart Images

Figure CN118976062A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of traditional Chinese medicine, and in particular to a composition for treating oral cancer, and a preparation method and application thereof. Background Art
[0002] Huangqin decoction is a classic Chinese medicine prescription with a history of 1,800 years. Its main ingredients are scutellaria, white peony root, liquorice, jujube, etc. It belongs to the heat-clearing medicine and is also a common prescription for the clinical treatment of dysentery and cancer in traditional Chinese medicine. Scutellaria has an inhibitory effect on a variety of bacteria and influenza viruses. With the effect of white peony root nourishing blood and restraining yin, liquorice and jujube have the functions of replenishing qi, nourishing blood, calming the nerves and alleviating the medicinal properties, it can produce anti-cancer and anti-cancer effects and reduce side effects. Huangqin decoction can also stimulate the growth of new intestinal stem cells and prevent and reduce inflammatory reactions. Therefore, the existing Huangqin decoction is mainly used for the adjuvant treatment of intestinal cancer, while Huangqin is widely used in the treatment of other cancers and malignant tumors, such as the anti-tumor combined composition and its application and anti-tumor drugs disclosed in the publication number CN 114870009A, in which berberine, baicalin and phellodendron chinense are used. Publication No. CN108514607A: A Chinese medicine composition for preventing malignant tumors, preparation method and application thereof, mainly prepared by compounding rhubarb, cyperus rotundus, evodia rutaecarpa, scutellaria baicalensis, phellodendron chinense, gardenia jasminoides, scutellaria baicalensis, angelica dahurica, radix trichosanthis, chuanxiong, licorice, peony bark, red cyathula and immature bitter orange, red ginseng, ophiopogon japonicus, longan pulp, ebony plum and hawthorn. Publication No. CN105288278A: A Chinese medicine microbial fermentation preparation for antitumor, preparation method and application thereof, scutellaria baicalensis, jujube and other Chinese medicine components are fermented with microorganism Pleurotus eryngii.
[0003] Oral squamous cell carcinoma (OSCC) is a common malignant tumor among oral diseases and a global disease with high morbidity and mortality. The most important treatment method currently is surgical resection, but oral cancer cells are still easy to spread after surgical resection, and the morbidity and mortality rates remain high. Summary of the invention
[0004] In order to solve the above problems, the present invention provides a composition for treating oral cancer, a preparation method and an application thereof, which can effectively inhibit the migration ability of human oral cancer cells and effectively assist in the treatment of oral cancer.
[0005] In order to achieve the above object, the present invention is implemented by the following technical solutions:
[0006] A composition for treating oral cancer comprises at least the following components: Radix Scutellariae, Radix Glycyrrhizae Preparata, Radix Paeoniae Alba and jujube.
[0007] Furthermore, the composition for treating oral cancer also includes Paris polyphylla and Sophora flavescens.
[0008] Furthermore, the composition for treating oral cancer includes the following components: 5-15 parts of Scutellaria baicalensis, 5-15 parts of Radix Glycyrrhizae Preparata, 5-15 parts of Radix Paeoniae Alba, 1-10 parts of Paris polyphyllae, 1-10 parts of Sophora flavescens, and 100-200 parts of jujube.
[0009] Furthermore, the composition for treating oral cancer includes the following components: 5-10 parts of Scutellaria baicalensis, 5-10 parts of Radix Glycyrrhizae Preparata, 5-10 parts of Radix Paeoniae Alba, 1-5 parts of Paris polyphyllae, 1-5 parts of Sophora flavescens, and 100-150 parts of jujube.
[0010] Further, 9 parts of Scutellaria baicalensis, 6 parts of Radix Glycyrrhizae Preparata, 6 parts of Radix Paeoniae Alba, 2 parts of Paris Polygoni Multiflori, 2 parts of Sophora flavescens, and 120 parts of Jujube.
[0011] The present invention also protects a method for preparing a composition for treating oral cancer, comprising the following steps: mixing Scutellaria baicalensis, Radix Glycyrrhizae Preparata, Radix Paeoniae Rubra, Rhizoma Paris Polygoni Multiflori, Radix Sophorae Flavescentis, jujube and water at a solid-liquid ratio of 1:3-5, first boiling over high heat for 15-30 minutes, then boiling over low heat for 1-3 hours, and filtering to obtain a decoction composition.
[0012] Furthermore, the method further comprises preparing the decoction composition obtained by boiling into a paste, granules, tablets or capsules by conventional preparation methods.
[0013] The present invention also protects the use of a composition for treating oral cancer in preparing oral disease medicines.
[0014] Furthermore, the oral diseases include oral inflammation, oral ulcers and oral squamous cell carcinoma.
[0015] Furthermore, the drug also includes pharmaceutically acceptable adjuvants, diluents, carriers or excipients.
[0016] The composition for treating oral cancer of the present invention, as well as its preparation method and application, has the beneficial effects that: the composition of traditional Chinese medicine of the present invention adopts a specific proportion, has the effects of clearing away heat, relieving inflammation and relieving pain, effectively inhibiting the migration ability of human oral cancer cells, effectively inhibiting the proliferation of oral squamous cell carcinoma cells, inducing apoptosis of oral squamous cell carcinoma cells, and effectively assisting in the treatment of oral cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.
[0018] Figure 1 The cell migration inhibition ability of the present invention on SCC25 and CAL27;
[0019] Figure 2 is a diagram showing the cytotoxic effect of CD8+T cells on tumor SCC25 and CAL2 cells in the presence of the present invention;
[0020] Figure 1 and Figure 2 In the figure, Control is a blank control group, HQD-L is an experimental group with the addition of a low-concentration decoction composition; HQD-M is an experimental group with the addition of a medium-concentration decoction composition; and HQD-H is an experimental group with the addition of a high-concentration decoction composition. DETAILED DESCRIPTION
[0021] In order to enable those skilled in the art to better understand the solution of the present invention, the technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0022] Example 1
[0023] A composition for treating oral cancer comprises the following components in parts by weight: 5 parts of Scutellaria baicalensis, 5 parts of Radix Glycyrrhizae Preparata, 5 parts of Radix Paeoniae Alba, 1 part of Paris Polygoni Multiflori, 1 part of Sophora flavescens and 100 parts of Jujube.
[0024] The preparation method of the composition of this embodiment comprises the following steps: mixing Scutellaria baicalensis, Radix Glycyrrhizae Preparata, Radix Paeoniae Rubra, Rhizoma Paris Polygoni Multiflori, Radix Sophorae Flavescentis, jujube and water at a solid-liquid ratio of 1:3, first boiling over high heat for 30 minutes, then boiling over low heat for 3 hours, and filtering to obtain a decoction composition.
[0025] Example 2
[0026] A composition for treating oral cancer comprises the following components in parts by weight: 15 parts of Scutellaria baicalensis, 15 parts of Radix Glycyrrhizae Preparata, 15 parts of Radix Paeoniae Alba, 10 parts of Paris Polygoni Multiflori, 10 parts of Sophora flavescens and 200 parts of jujube.
[0027] The preparation method of the composition of this embodiment comprises the following steps: mixing Scutellaria baicalensis, Radix Glycyrrhizae Preparata, Radix Paeoniae Rubra, Rhizoma Paris Polygoni Multiflori, Radix Sophorae Flavescentis, jujube and water at a solid-liquid ratio of 1:5, first boiling over high heat for 15 minutes, then boiling over low heat for 2 hours, filtering to obtain a decoction composition, and then concentrating and drying to obtain composition particles.
[0028] Example 3
[0029] A composition for treating oral cancer comprises the following components in parts by weight: 10 parts of Scutellaria baicalensis, 10 parts of Radix Glycyrrhizae Preparata, 10 parts of Radix Paeoniae Alba, 5 parts of Paris Polygoni Multiflori, 5 parts of Sophora flavescens and 150 parts of jujube.
[0030] The preparation method of the composition of this embodiment comprises the following steps: mixing Scutellaria baicalensis, Radix Glycyrrhizae Preparata, Radix Paeoniae Rubra, Rhizoma Paris Polygoni Multiflori, Radix Sophorae Flavescentis, jujube and water at a solid-liquid ratio of 1:3, first boiling over high heat for 15 minutes, then boiling over low heat for 2 hours, filtering to obtain a decoction composition, and concentrating and drying to obtain a composition powder.
[0031] Example 4
[0032] A composition for treating oral cancer comprises the following components in parts by weight: 9 parts of Scutellaria baicalensis, 6 parts of Radix Glycyrrhizae Preparata, 6 parts of Radix Paeoniae Alba, 2 parts of Paris Polygoni Multiflori, 2 parts of Sophora flavescens and 120 parts of jujube.
[0033] The preparation method of the composition of this embodiment comprises the following steps: mixing Scutellaria baicalensis, Radix Glycyrrhizae Preparata, Radix Paeoniae Rubra, Rhizoma Paris Polygoni Multiflori, Radix Sophorae Flavescentis, jujube and water at a solid-liquid ratio of 1:5, first boiling over high heat for 15 minutes, then boiling over low heat for 3 hours, boiling until the solid-liquid ratio is 1:1-1.5, and filtering to obtain a decoction composition.
[0034] The decoction obtained in this example is used in the treatment of human oral squamous cell carcinoma cells. The recommended dosage for adults is 120-200 g / day. It can be taken before and after surgery and taken continuously for no less than 7 days.
[0035] 1. Cell migration inhibition test
[0036] 1.1. Experimental cells: human oral squamous cell carcinoma cell lines SCC25 and CAL27;
[0037] Test samples: the decoction composition obtained in Example 4 was prepared into high-dose, medium-dose and low-medium-dose drug-containing serum of Huangqin Decoction;
[0038] Preparation of drug-containing serum: Wistar rats (80 rats, weighing about 200g) were randomly divided into 4 groups: low-dose, medium-dose, high-dose Huangqin decoction groups, and normal saline groups. Low-dose, medium-dose, and high-dose Huangqin decoction were given by gavage, respectively; the control group was given an equal amount of normal saline by gavage. The recommended clinical dosage of Huangqin decoction for adults is 160g per day. According to the equivalent ratio table of human and animal body surface areas, the equivalent amount for rats is 4 times that of adults, taking the approximate value of 70g / kg, and the gavage volume is 1.5mL / 100g, and the gavage concentration of Huangqin decoction is 2.2mg / mL. 2.2mg / mL was set as the concentration of the low-dose group, 2 times (i.e., 4.4mg / mL) for the medium-dose group, and 4 times (i.e., 8.8mg / mL) for the high-dose group. The rats were gavaged once a day for 7 days. Two hours after the last medication, the rats were anesthetized with 3.5% (0.9 mL / 100 g) chloral hydrate. Blood was collected from the femoral artery under sterile conditions and centrifuged at 3000 rpm for 10 minutes. The supernatant was separated, filtered through a 0.22 μm filter membrane for sterilization, and stored at -20°C for later use after labeling. The high-dose serum, medium-dose serum, low-dose serum and blank control group serum (Control) were obtained.
[0039] 1.2 Methods
[0040] 1.2.1 Cell culture
[0041] Human oral squamous cell carcinoma cells SCC25 and CAL27 were cultured in DMEM high-glucose medium containing 10% fetal bovine serum and 1% double-antibody (penicillin + streptomycin) during the logarithmic growth period. After that, they were trypsinized and resuspended. The cell suspension was adjusted to a concentration of 1×10 4 The cells were inoculated at a density of 100 μg / well in a 96-well plate and cultured in a cell culture incubator at 37°C, 5% CO2, and saturated humidity for 24 h. After the cells adhered to the wall, they were used for subsequent experiments.
[0042] 1.2.2 Cell survival
[0043] The cell suspension was adjusted to a concentration of 1×10 4 / well were inoculated in a 96-well plate, and different concentrations (high-dose drug-containing serum, medium-dose drug-containing serum and low-dose drug-containing serum) of Huangcen Decoction drug-containing serum culture medium were added (100μL / well), and 3 parallel wells were set up in each group. 20μL MTT solution (5mg / mL) was added to each well, and 20μL MTT solution (5mg / mL) was added to each well. After incubation for 48h, the culture medium in the well was aspirated, and 150μL dimethyl sulfoxide was added to each well. The plate was placed on a shaker in the dark and oscillated at a low speed for 10min to fully dissolve the crystals. The absorbance value (OD value) of each well was measured at a wavelength of 490nm on an enzyme-linked immunosorbent assay, and the IC 50 The cell survival rate of each group was calculated.
[0044] The MTT test results of each group showed that compared with the blank control group, the cell viability of cells treated with the high-dose drug-containing serum, medium-dose drug-containing serum and low-dose drug-containing serum of the present invention was reduced, and the results were statistically significant (P<0.01).
[0045] 1.2.3 Scratch test
[0046] Use a marker pen to draw horizontal lines on the back of the 6-well plate with a ruler, each about 1 cm apart, across the wells. The cell density in the 6-well plate was 1×10 6 / mL of SCC25 and CAL27 cells. Cultured in a cell culture incubator at 37°C, 5% CO2, and saturated humidity for 48 hours. On the second day, use a 1mL pipette tip to draw a line in the 6-well plate along the ruler, perpendicular to the horizontal line on the back. Wash the cells three times with sterile PBS, then replace the culture medium in the well with serum-free culture medium, add high-dose drug-containing serum, medium-dose drug-containing serum, and low-dose drug-containing blood, respectively, use a microscope to take pictures and mark the aperture position and number for each picture with a marker. Take pictures of 4-5 positions in each duplicate well. After culturing the cells in a cell culture incubator at 37°C, 5% CO2, and saturated humidity for 48 hours, use a microscope to take pictures at the corresponding positions. Use ImageJ software to analyze the images, such as Figure 1 shown.
[0047]
[0048] The results of the scratch test showed that the number of migration rates in the blank control group was significantly higher than that in the experimental group, indicating that the drug-containing serum containing the composition of the present invention can inhibit the migration ability of oral squamous cell carcinoma cells SCC25 and CAL27, can effectively prevent the spread of oral squamous cell carcinoma cells SCC25 and CAL27, and has a positive effect on the prevention and treatment of oral squamous cell carcinoma.
[0049] 2. Cytotoxicity Test
[0050] Human oral cancer cells and CD8 + T cell co-culture experiment: human oral cancer cells SCC25 and CAL27 and activated lung cancer tumor CD8 + T cells were co-cultured in transwells;
[0051] Set up a control group (also called a model group) and an experimental group; no other reagents are added to the control group;
[0052] Experimental group: divided into 3 groups, each with 3 replicates; co-cultured in transwell for 48h; HQD-L was added with 1mL of low-concentration 2.2mg / mL decoction; HQD-M was added with 1mL of medium-concentration 4.4mg / mL decoction; HQD-H was added with 1mL of high-concentration 8.8mg / mL decoction. Detection of CD8 + The results of T cell cytotoxicity against tumor cells are as follows Figure 2 shown.
[0053] from Figure 2 It can be seen that the groups treated with low, medium and high compositions of the present invention significantly increased the number of CD8 + The number of T cells was increased, and under the conditions of high concentration and medium concentration, the number was significantly increased, indicating that the present invention has a good effect of resisting human oral cancer cells.
[0054] Reference to "embodiments" herein means that a particular feature, structure, or characteristic described in conjunction with the embodiments may be included in at least one embodiment of the present invention. The appearance of the phrase in various places in the specification does not necessarily refer to the same embodiment, nor is it an independent or alternative embodiment that is mutually exclusive with other embodiments. It is explicitly and implicitly understood by those skilled in the art that the embodiments described herein may be combined with other embodiments.
[0055] Finally, it should be noted that the embodiments disclosed in the present invention are only preferred embodiments of the present invention, which are only used to illustrate the technical solutions of the present invention rather than to limit them. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that the technical solutions described in the aforementioned embodiments may still be modified, or some of the technical features may be replaced by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the various embodiments of the present invention.
Claims
1. A composition for treating oral cancer, characterized in that: It at least includes the following components: Scutellaria baicalensis, roasted liquorice root, peony root and jujube.
2. The composition for treating oral cancer according to claim 1, characterized in that: It also includes Paris polyphylla and Sophora flavescens.
3. The composition for treating oral cancer according to claim 2, characterized in that: The invention comprises the following components in parts by weight: 5-15 parts of scutellaria baicalensis, 5-15 parts of licorice root, 5-15 parts of peony root, 1-10 parts of parsley, 1-10 parts of sophora flavescens and 100-200 parts of jujube.
4. The composition for treating oral cancer according to claim 2, characterized in that: 5-10 parts of Scutellaria baicalensis, 5-10 parts of Radix Glycyrrhizae Preparata, 5-10 parts of Radix Paeoniae Alba, 1-5 parts of Paris Polygoni Multiflori, 1-5 parts of Sophora flavescens, and 100-150 parts of Jujube.
5. The composition for treating oral cancer according to claim 2, characterized in that: 9 parts of Radix Scutellariae, 6 parts of Radix Glycyrrhizae Preparata, 6 parts of Radix Paeoniae Alba, 2 parts of Rhizoma Polygoni Multiflori, 2 parts of Radix Sophorae Flavescentis, and 120 parts of Radix Jujubae.
6. A method for preparing the composition for treating oral cancer according to any one of claims 1 to 5, characterized in that: The following steps are involved: Mix Scutellaria baicalensis, roasted liquorice, peony root, Paris polyphylla, Sophora flavescens, jujube and water at a solid-liquid ratio of 1:3-5, first boil over high heat for 15-30 minutes, then boil over low heat for 1-3 hours, and filter to obtain a decoction composition.
7. The method for preparing the composition for treating oral cancer according to claim 6, characterized in that: The method also includes preparing the decoction composition obtained by boiling into paste, granules, tablets or capsules through conventional preparation methods.
8. Use of a composition for treating oral cancer in the preparation of oral disease medicines.
9. The use according to claim 8, characterized in that: The oral diseases include oral inflammation, oral ulcers and oral squamous cell carcinoma.
10. The use according to claim 8, characterized in that: The drug also includes pharmaceutically acceptable adjuvants, diluents, carriers or excipients.
Citation Information
Patent Citations
Invasion inhibitor for oral cancer cell
JP2013079215A
